Achievements of Scott Rocklage of 5AM Ventures

Scott M. Rocklage a managing partner of 5AM Ventures. Why 5AM? The company got this name because it is involved in activities of helping business at their early stages. 5AM Ventures is precisely involved in the business of company formation.

Scott joined 5AM in 2003 as a venture partner but within a year he had grown to the position of a managing partner. Scott Rocklage is a holder of a degree in Chemistry from the University of California. Scott Rocklage has over 20 years of experience serving in the healthcare department. Read more: Scott Racklage | Crunchbase and Scott Rocklage | LinkedIn

He has served in various leadership positions while in this field. One of this major achievement was the approval of three drug application by the Food and Drugs Agency (FDA). These drugs are Teslascan®, Omniscan™, and Cubicin®). He has also had 6 other drugs undergone the clinical trials.

Scott Rocklage has been the CEO and Chairman of Cubist Pharmaceuticals as well as the President of Nycomed Salutar. Other positions he has held are CEO of Nycomed Interventional and R&D position at Catalytica. Scott currently serves at the Achaogen, Relypsa, and Semprus as the Board chairman. He also serves on the board of WaveRx.

At some point in his career, he worked as the Executive Chairman of llypsa, now known as Amgen and also MIIkana, now known as EntreMed. It’s therefore clear that Scott Rocklage has had a very successful career working at esteemed positions for some of the big players in the healthcare industry.

Scott Rocklage spends most of his time doing research in the field of life science and working with company’s portfolio management teams. He also spends time attending board meeting, since he has a long list of organizations where he is an ordinary board member if not the chairman. Scott explains that his work is to find solutions to medical needs.

He, therefore, works with physicians, scientists and business leaders to help get these solutions. Scott Rocklage prides himself in making great progress in the creation of a cancer treatment methodology that has the capability of extending patients’ lives considerably. He says that his focus still remains in this area of research and hope to make further improvements.